A Prospective Observational Cohort Study for Newly Diagnosed Osteosarcoma Patients in the UK: ICONIC Study Initial Results

Author:

Childs Alexa1,Gerrand Craig2ORCID,Brennan Bernadette3,Young Robin4,Rankin Kenneth S.5,Parry Michael6,Stevenson Jonathan6ORCID,Flanagan Adrienne M.27,Taylor Rachel M.1ORCID,Fern Lorna1ORCID,Heymann Dominique89ORCID,Vance Filipa10,Sherriff Jenny11ORCID,Singh Saurabh12,Begum Rubina13ORCID,Forsyth Sharon L.13ORCID,Reczko Krystyna13,Sparksman Kate13,Wilson William13,Strauss Sandra J.17ORCID

Affiliation:

1. University College London Hospitals NHS Foundation Trust, 250 Euston Road, London NW1 2PG, UK

2. The Royal National Orthopaedic Hospital Trust, Brockley Hill, Stanmore HA7 4LP, UK

3. Royal Manchester Children’s Hospital, Oxford Road, Manchester M13 9WL, UK

4. Sheffield Teaching Hospitals NHS Foundation Trust, Weston Park Hospital, Whitham Road, Broomhall, Sheffield S10 2JF, UK

5. Newcastle Centre Cancer, Paul O’Gorman Building, Framlington Place, Newcastle upon Tyne NE2 4AD, UK

6. The Royal Orthopaedic Hospital NHS Foundation Trust, Bristol Road South, Northfield, Birmingham B31 2AP, UK

7. UCL Cancer Institute, London WC1E 6DD, UK

8. Sarcoma Research Unit, Department of Oncology & Metabolism, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK

9. Nantes Université, CNRS, UMR6286, US2B, Institut de Cancérologie de l’Ouest, 44800 Saint-Herblain, France

10. ICONIC Patient Representative

11. Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Edgbaston, Birmingham B15 2GW, UK

12. Centre for Medical Imaging, University College London, London WC1E 6BT, UK

13. CRUK & UCL Cancer Trials Centre, University College London, 90 Tottenham Court Road, London W1T 4TJ, UK

Abstract

There has been little change to the standard treatment for osteosarcoma (OS) over the last 25 years and there is an unmet need to identify new biomarkers and novel therapeutic approaches if outcomes are to improve. Furthermore, there is limited evidence on the impact of OS treatment on patient-reported outcomes (PROs). ICONIC (Improving Outcomes through Collaboration in Osteosarcoma; NCT04132895) is a prospective observational cohort study recruiting newly diagnosed OS patients across the United Kingdom (UK) with matched longitudinal collection of clinical, biological, and PRO data. During Stage 1, which assessed the feasibility of recruitment and data collection, 102 patients were recruited at 22 sites with representation from patient groups frequently excluded in OS studies, including patients over 50 years and those with less common primary sites. The feasibility of collecting clinical and biological samples, in addition to PRO data, has been established and there is ongoing analysis of these data as part of Stage 2. ICONIC will provide a unique, prospective cohort of newly diagnosed OS patients representative of the UK patient population, with fully annotated clinical outcomes linked to molecularly characterised biospecimens, allowing for comprehensive analyses to better understand biology and develop new biomarkers and novel therapeutic approaches.

Funder

Bone Cancer Research Trust

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3